Julien Diana Inserm research fellow Inserm Unit 1151 « Institut Necker-Enfants Malades » (Inserm/CNRS/Université Paris Descartes) +33 (0) 1 44 49 50 69 Julien.email@example.com
Our bodies have ten times the amount of microbes than human cells. This set of bacteria is called microbiota. In some instances, bacteria known as pathogens can cause infectious diseases. However, these micro-organisms can also protect us from certain diseases. Researchers from Inserm, Paris Descartes University and the CNRS (French National Centre for Scientific Research), through collaboration with teams from China and Sweden, have recently shown how microbiota protects against the development of type 1 diabetes. This research is published in the Immunity journal, 4 August 2015.
A pancreatic islet of Langerhans expressing the immunoregulator antimicrobial peptide CRAM (in red). The insulin-producting beta-cells are in green and the glucagon-producting alpha-cells are in blue. © Julien Diana
To combat pathogens, the immune system has developed various mechanisms to detect, defend against and even destroy micro-organisms that are harmful to the body. This includes antimicrobial peptides and natural proteins that destroy pathogenic bacteria by disrupting their cellular membrane. Not only are they produced by immune cells, they are also produced by cells whose functions are not immune-related.
A research team coordinated by Julien Diana, an Inserm Research Fellow at Inserm Unit 1151 “Institut Necker-Enfant Malades” [Necker Institute for Sick Children] (Inserm/CNRS/Université Paris Descartes), is focussing on a category of antimicrobial peptides, i.e. cathelicidins. Apart from their protective function, these peptides have also exhibited immunoregulatory abilities against several autoimmune diseases. As such, scientists hypothesise that cathelicidins may be involved in the control of type 1 diabetes, an autoimmune disease where certain cells in the immune system attack beta cells in the pancreas which secrete insulin.
Firstly, they observed that beta pancreatic cells in non-diseased mice produce cathelicidins and that, interestingly, this production is impaired in diabetic mice.
To test this hypothesis, they are injecting diabetic mice with cathelicidins where production is defective.
“Injecting cathelicidins inhibits the development of pancreatic inflammation and, as such, suppresses the development of autoimmune disease in these mice” states Julien Diana.
Given that the production of cathelicidins is controlled by short-chain fatty acids produced by gut bacteria, Julien Diana’s team are studying the possibility that this may by the cause of the cathelicidin deficiency associated with diabetes. Indeed, researchers have observed that diabetic mice have a lower level of short-chain fatty acids than that found in healthy mice.
By transferring part of the gut bacteria from healthy mice to diabetic mice, they are re-establishing a normal level of cathelicidin. Meanwhile, the transfer of micro-organisms reduces the occurrence of diabetes.
For the authors, “this research is further evidence of the undeniable role microbiota plays in autoimmune diseases, particularly in controlling the development of autoimmune diabetes”. Preliminary data, as well as scientific literature, suggest that a similar mechanism may exist in humans, paving the way for new therapies against autoimmune diabetes.
Adenomatous polyposis coli (APC) is a gene whose mutations are associated with a rare, hereditary form of colorectal cancer known as familial adenomatous polyposis. Research led by scientists at the Institut Pasteur and Inserm have recently demonstrated that mutations to this gene ...
Scientists have finally observed the hepatitis C virus (or HCV) using an electron microscope. This is the first time since the virus became known in 1990. Inserm researchers at Tours (Inserm unit 966, “HIV and Hepatitis Viruses: Morphogenesis and Antigenicity”) have taken ...
Pancreatic beta-cells limit autoimmune diabetes via an immunoregulatory antimicrobial peptide expressed under the influence of the gut microbiota Jia Sun1, Laetitia Furio2,3, Ramine Mecheri3, Anne M. van der Does4, Erik Lundeberg4, Loredana Saveanu3,5, Yongquan Chen1, Peter van Endert3,5, Birgitta Agerberth6, Julien Diana3,5. 1 State Key Laboratory of Food Science and Technology, Synergetic Innovation Center of Food Safety and Nutrition and School of Food Science and Technology, Jiangnan University, 1800 Lihu Avenue Wuxi, 214122 Jiangsu, P. R. China; 2 Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 1163, Institut Imagine, 24 boulevard du Montparnasse, 75015 Paris, France; 3 Université Paris Descartes, Sorbonne Paris Cité, 12 Rue de l’École de Médecine, 75006 Paris, France; 4 Department of Physiology and Pharmacology, Karolinska Institutet, SE-141 86 Stockholm, Sweden; 5Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 1151, Institut Necker-Enfants Malades (INEM), Centre National de la Recherche Scientifique, Unité 8253, 149 rue de Sèvres, 75015 Paris, France; 6 Medical Microbial Pathogenesis Department of Laboratory Medicine, Clinical Microbiology, Karolinska Institutet Karolinska University Hospital, SE-141 86 Stockholm, Sweden. Immunity, 4 August 2015